The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer [clinicaltrials:NCT00097344]
The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer [clinicaltrials:NCT00097344]
Bio2RDF identifier
NCT00097344
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00097344
identifiers.org URI
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
The purpose of this stu ...... he side effects of letrozole.
brief title [clinicaltrials_vocabulary:brief-title]
The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
completion date [clinicaltrials_vocabulary:completion-date]
2006-08-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
Aromatase is an enzyme ...... romatase inhibitor letrozole.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
enrollment [clinicaltrials_vocabulary:enrollment]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2004-11-22T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
keyword [clinicaltrials_vocabulary:keyword]
Aromatase inhibitor
Atamestane
Breast neoplasms
Combined hormonal therapy
Complete estrogen blockade
Ductal breast carcinoma
Estrogen blocker
First line therapy
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2007-08-21T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00097344
official title [clinicaltrials_vocabulary:official-title]
Phase 3 Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
org study id [clinicaltrials_vocabulary:org-study-id]
Biomed 777-CLP-30
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
2004-12-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2007-08-01T00:00:00Z
why stopped [clinicaltrials_vocabulary:why-stopped]
Identical study Biomed 777-CLP-029 did not meet superiority endpoint
identifier
clinicaltrials:NCT00097344
title
The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
@en
type
label
The CAT Study: Atamestane Plus ...... r [clinicaltrials:NCT00097344]
@en